This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Other. Active years: 2016-2019.
Company Filing History:
2 out of 834,411 Years Active: 2016-2019
Title: Gerald Schumann: Innovator in Monoclonal Antibodies and Retrotransposons
Introduction
Gerald Schumann is a notable inventor based in Dreieich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies and methods for early detection of cell transformation in pre-neoplastic tissues. With a total of 2 patents, his work has implications for cancer treatment and diagnostics.
Latest Patents
Schumann's latest patents include a monoclonal antibody targeting the human Long Interspersed Element-1 ORF2 encoded protein (L1-ORF2p). This invention is crucial for predicting the response of cancer patients to NNRTI treatments. Additionally, he has developed a method for early detection of cell transformation in pre-neoplastic tissues, which involves detecting L1-ORF2p expression in tissue samples. This method can indicate the presence of cell transformation and monitor the progression of colon adenoma in affected individuals. Another significant invention relates to nucleic acids and vector constructs that allow controlled activation and inhibition of retrotransposition of non-LTR retrotransposons.
Career Highlights
Throughout his career, Schumann has worked with reputable organizations, including the Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe. His expertise in biotechnology has positioned him as a key figure in the development of innovative solutions for medical challenges.
Collaborations
Schumann has collaborated with esteemed colleagues such as Paola Sinibaldi-Vallebona and Chiara De Luca. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Gerald Schumann's contributions to the field of biotechnology through his patents and collaborations highlight his role as an innovator. His work continues to impact cancer diagnostics and treatment methodologies.